Theravance Biopharma, Inc.
TBPH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583107
In the last 90 days, Theravance Biopharma, Inc. insiders filed 0 open-market purchases and 3 sales; 179 institutions reported holding it in 13F filings for Q2 2026, worth $817.5M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $6.14M in total
- 3
- 13F holdersQ2 2026, +9 vs. previous quarter
- 179
- 13F valueReported value at the end of Q2 2026
- $817.5M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TBPH, Q2 2026
No superinvestor reported holding TBPH at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Theravance Biopharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)5:52 PM ET | Sep 15 | 2 days | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | SSale | −13.3K | $17.03 | −$226.8K | −5.9%213.5K after | 3 lots10b5-1 |
| Jul 8, 2026 (view filing)4:13 PM ET | Jul 6-7 | 2 days | Samaha Eli10% Owner | SSaleCOM | −6.96K | $17.14 | −$119.4K | −0.1%9.17M after | 2 lots |
| Jul 1, 2026 (view filing)7:33 PM ET | Jun 29-Jul 1 | 2 days | Samaha Eli10% Owner | SSaleCOM | −336.7K | $17.20 | −$5.79M | −3.5%9.17M after | 3 lots |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | SSale | −13.3K | $16.39 | −$218.2K | −5.4%232.5K after | 3 lots10b5-1 |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | SSale | −31.1K | $13.96 | −$433.7K | −11.8%232.7K after | 3 lots10b5-1 |
| Dec 5, 2025 (view filing) | Dec 3 | 2 days | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | SSale | −31.1K | $18.75 | −$582.5K | −10.1%277.7K after | 3 lots10b5-1 |
| Dec 1, 2025 (view filing) | Nov 26 | 5 days | Broshy EranDirector | SSale | −29.5K | $20.00 | −$590.0K | −39.8%44.7K after | 2 lots10b5-1 |
| Nov 14, 2025 (view filing) | Nov 11 | 3 days | Broshy EranDirector | SSale | −45.0K | $17.98 | −$809.3K | −42.8%60.2K after | Amended3 lots |
| Jul 16, 2025 (view filing) | Jul 14 | 2 days | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | SSale | −10.0K | $11.39 | −$113.9K | −3.0%326.9K after | 3 lots10b5-1 |
| Jun 4, 2025 (view filing) | Jun 2 | 2 days | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | SSale | −24.0K | $11.00 | −$264.0K | −6.6%336.9K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Theravance Biopharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Madison Avenue Partners, LP | 9,212,252 | $156.6M | 6.74% | −298,898−3.1% | Reduced |
| Weiss Asset Management LP | 7,457,060 | $126.8M | 1.42% | 00.0% | Unchanged |
| BlackRock, Inc. | 4,562,487 | $77.6M | 0.00% | +266,197+6.2% | Added |
| Newtyn Management, LLC | 3,434,191 | $58.4M | 7.29% | −1,407,438−29.1% | Reduced |
| Irenic Capital Management LP | 2,760,948 | $46.9M | 3.38% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 1,771,493 | $30.1M | 0.00% | −12,260−0.7% | Reduced |
| State Street Corp | 1,328,584 | $22.6M | 0.00% | +31,261+2.4% | Added |
| Two Sigma Investments, LP | 1,225,587 | $20.8M | 0.02% | −32,910−2.6% | Reduced |
| D. E. Shaw & Co., Inc. | 1,185,390 | $20.2M | 0.01% | +231,348+24.2% | Added |
| Acadian Asset Management LLC | 1,174,910 | $20.0M | 0.02% | −101,666−8.0% | Reduced |